A real-world study of new hepatitis C
protease inhibitors in the group of patients who have been told they should not
wait for newer, experimental antivirals has shown a much higher rate of serious
adverse events and treatment discontinuations than in clinical trials, Dr
Christophe Hézode reported on behalf of the French Compassionate Use of
Protease Inhibitors in Cirrhotics cohort study at the 2012 International Liver Congress in
Barcelona on Thursday.
However, rates of virologic response after 16 weeks of treatment were high in this group of patients, who had previously relapsed or failed to respond to pegylated interferon and ribavirin.
The programme and cohort study were established
prior to the licensing of telaprevir (Incivo/Incivek)
and boceprevir (Victrelis) in Europe,
in order to provide early access to the new drugs in patients with hepatitis C
judged to be in urgent need of treatment. Under French law, experimental drugs may be made available prior to licensing to patients with urgent clinical needs, if data on safety are collected.
- compensated cirrhosis
The earlier stage of
cirrhosis, during which the liver is damaged but still able to perform most of
its functions. See also ‘cirrhosis’ and ‘decompensated cirrhosis’.
A shortage of neutrophils, a type of white blood
cell that fights bacterial infections.
The cohort study sought to evaluate
outcomes in people who received the drugs, and in particular to evaluate the
tolerability and efficacy of the new drugs in people with hepatitis C mono-infection
and compensated cirrhosis with a previous history of non-response or relapse
after standard treatment with pegylated interferon and ribavirin.
Early access was provided to telaprevir or
boceprevir for 655 patients at 55 hospitals in France; 455 were eligible for
inclusion in the cirrhosis analysis (296 telaprevir, 149 boceprevir).
The telaprevir regimen consisted of twelve
weeks of telaprevir in combination with standard hepatitis C treatment,
followed by a further 36 weeks of pegylated interferon and ribavirin. The
boceprevir regimen comprised four weeks of lead-in treatment with pegylated interferon
and ribavirin, followed by 44 weeks of boceprevir with pegylated interferon and
ribavirin. This study did not report on sustained virologic response after completion
of treatment and efficacy and adverse event data over the first 16 weeks of
treatment. However, week 16 on-treatment virologic response data showed that 86% (177 of 205 patients) of telaprevir-treated patients and 71% (89 of 126) of boceprevir-treated patients had undetectable hepatitis C viral load.
There was no randomisation, which precluded
any comparison between the safety profiles of the two drugs.
Most of the patients were male and their
mean age was 57 years.
Just under half (48.6%) of patients
receiving telaprevir experienced a serious adverse event as did 38% of those
treated with boceprevir. This high prevalence of serious side-effects contrasted
to the rates of between 9 and 14% observed in the phase III studies which led
to the licensing of the drugs. 14.5% of the telaprevir-treated
patients and 7% of the boceprevir-treated patients discontinued treatment as a
result of serious adverse events.
“The safety profile of telaprevir or
boceprevir with pegylated interferon/ribavirin in cirrhotic patients was poor,”
comment the investigators.
Grade 2 anaemia (definted as 8.0-10.0 g/dl)
developed in 19.6% of telaprevir-treated patients and 22% of individuals
receiving boceprevir-based therapy. Grade 3-4 anaemia (< 8.0 g/dl) was
observed in 10% of those taking telaprevir and 10% of patients treated with
EPO therapy for anaemia was provided to 56%
of telaprevir patients and 66% of boceprevir patients. A fifth of people
taking telaprevir and 10% of those treated with boceprevir required a blood
Serious (grade 3-4, < 50,000/mm3)
thrombopenia was also common. It developed in 13 and 7% of telaprevir and
boceprevir-treated patients respectively. Neutropenia grade 3-4 ( < 1000/mm3)
was observed in 5% of telaprevir and boceprevir-treated patients.
Although serious infections were rare (1 to 2%), a large proportion of patients developed other grade 3-4 adverse events such as rash, pruritis and hepatic decompensation
(53% telaprevir; 32% boceprevir).
“These data strongly suggest that triple
therapy must be administered cautiously with intensive safety monitoring
in…patients [with cirrhosis],” conclude the investigators.